INmune Bio (NASDAQ:INMB) Rating Increased to Strong-Buy at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of INmune Bio (NASDAQ:INMB) to a strong-buy rating in a research note published on Tuesday,Zacks.com reports.

A number of other equities analysts also recently commented on INMB. Alliance Global Partners started coverage on shares of INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 price objective for the company. Rodman & Renshaw assumed coverage on INmune Bio in a research note on Tuesday. They set a “buy” rating and a $23.00 price objective for the company. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $20.75.

INmune Bio Price Performance

INMB opened at $8.02 on Tuesday. INmune Bio has a 12-month low of $4.32 and a 12-month high of $14.74. The business’s fifty day simple moving average is $5.44 and its 200-day simple moving average is $6.04.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). During the same period in the prior year, the firm earned ($0.48) EPS. Equities analysts predict that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Institutional Trading of INmune Bio

Hedge funds and other institutional investors have recently made changes to their positions in the business. Financial Advocates Investment Management increased its position in INmune Bio by 14.8% during the 4th quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock valued at $72,000 after buying an additional 2,000 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of INmune Bio during the third quarter worth about $79,000. Sanctuary Advisors LLC acquired a new position in shares of INmune Bio during the third quarter valued at about $113,000. Barclays PLC raised its position in shares of INmune Bio by 601.9% in the 3rd quarter. Barclays PLC now owns 29,044 shares of the company’s stock valued at $157,000 after purchasing an additional 24,906 shares during the last quarter. Finally, Fermata Advisors LLC boosted its stake in INmune Bio by 10.0% in the 4th quarter. Fermata Advisors LLC now owns 46,997 shares of the company’s stock worth $219,000 after purchasing an additional 4,267 shares in the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.